CohBar is a clinical stage biotechnology company utilizing the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In addition, Co. has multiple preclinical programs, such as a program in acute respiratory distress syndrome as well as earlier stage discovery programs. Co.'s pipelines include: CB5138-3, which is for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases; CB4211, which is for the treatment of nonalcoholic steatohepatitis and obesity; and CB5064 Analogs, family of peptides that are agonists of the apelin receptor. The CWBR average annual return since 2017 is shown above.
The Average Annual Return on the CWBR average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CWBR average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CWBR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CWBR Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
